Arcoma (ARCOMA) Stock Overview
Develops, produces, and provides radiology solutions and digital x-ray systems in Sweden and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ARCOMA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Arcoma AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 8.46 |
| 52 Week High | SEK 11.00 |
| 52 Week Low | SEK 6.16 |
| Beta | 0.64 |
| 1 Month Change | -7.84% |
| 3 Month Change | 1.44% |
| 1 Year Change | -12.78% |
| 3 Year Change | -9.52% |
| 5 Year Change | -54.88% |
| Change since IPO | -38.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| ARCOMA | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | 0.7% | 0.6% | -1.3% |
| 1Y | -12.8% | -10.5% | 8.6% |
Return vs Industry: ARCOMA underperformed the Swedish Medical Equipment industry which returned -10.5% over the past year.
Return vs Market: ARCOMA underperformed the Swedish Market which returned 8.6% over the past year.
Price Volatility
| ARCOMA volatility | |
|---|---|
| ARCOMA Average Weekly Movement | 9.1% |
| Medical Equipment Industry Average Movement | 7.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in SE Market | 12.8% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: ARCOMA's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: ARCOMA's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 31 | Mattias Leire | www.arcoma.se |
Arcoma AB develops, produces, and provides radiology solutions and digital x-ray systems in Sweden and internationally. The company offers solutions for x-ray systems covering radiological applications and general, eneral, muscle/skeleton, thoratic, pediatric, and trauma/resus clinics. It also provides x-ray detectors; video bank; and accessories for x-ray equipment comprising live camera, advanced remote control, form pad, hand control, compression belt, detector holder, foot control, lateral armrest, patient handgrip, mattress, scatter correction software, battery charger, battery pack, and stitching screen.
Arcoma AB Fundamentals Summary
| ARCOMA fundamental statistics | |
|---|---|
| Market cap | SEK 121.05m |
| Earnings (TTM) | SEK 3.80m |
| Revenue (TTM) | SEK 127.06m |
Is ARCOMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARCOMA income statement (TTM) | |
|---|---|
| Revenue | SEK 127.06m |
| Cost of Revenue | SEK 76.43m |
| Gross Profit | SEK 50.63m |
| Other Expenses | SEK 46.83m |
| Earnings | SEK 3.80m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 20, 2026
| Earnings per share (EPS) | 0.27 |
| Gross Margin | 39.84% |
| Net Profit Margin | 2.99% |
| Debt/Equity Ratio | 0% |
How did ARCOMA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/09 22:51 |
| End of Day Share Price | 2026/07/09 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Arcoma AB is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hjalmar Jernstrom | DNB Carnegie Commissioned Research |